PAVmed (PAVM) Cash & Equivalents (2015 - 2025)

PAVmed's Cash & Equivalents history runs 11 years deep, the most recent figure standing at $1.5 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 26.58% year-over-year to $1.5 million; the TTM figure through Dec 2025 stood at $1.5 million (up 26.58% YoY), while the FY2025 annual figure was $1.5 million, up 26.58% from the prior year.
• Cash & Equivalents was $1.5 million for Q4 2025 at PAVmed, down from $3.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $77.3 million in Q4 2021 to a low of $1.2 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $32.3 million across 5 years, with a median of $31.8 million in 2023.
• The sharpest annual moves came in 2021 and 2024: Cash & Equivalents soared 510.31% in 2021, then sank 93.97% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $77.3 million in 2021, then plunged by 48.56% to $39.7 million in 2022, then tumbled by 50.59% to $19.6 million in 2023, then tumbled by 93.97% to $1.2 million in 2024, then grew by 26.58% to $1.5 million in 2025.
• The last three Cash & Equivalents figures came in at $1.5 million (Q4 2025), $3.1 million (Q3 2025), and $4.0 million (Q2 2025), per Business Quant data.